MHRA response to AstraZeneca coronavirus (COVID-19) vaccine suspension

MHRA response to AstraZeneca coronavirus (COVID-19) vaccine suspension

The Medicines and Healthcare products Regulatory Agency (MHRA) has released its response to the action taken by Danish, Norwegian and Icelandic authorities to temporarily suspend their distribution of the AstraZeneca coronavirus (COVID-19) vaccine in light of an unconfirmed report of a blood clot caused by the vaccine. MHRA Vaccines Safety Lead, Dr Phil Bryan, said that these temporary suspensions are ‘precautionary’, and that the MHRA is continuing to ‘monitor the safety of vaccines to ensure that the benefits outweigh any potential risks’.

Bryan said that the number of reports of blood clots, which can occur naturally and are not uncommon, is not higher than would have occurred naturally among those who have had the AstraZeneca vaccine. The MHRA is reviewing the evidence but has said that it does not suggest that the vaccine is the cause. Bryan concluded by saying that ‘people should still go and get their COVID-19 vaccine when asked to do so’.


• MHRA response to Danish, Norwegian and Icelandic authorities’ action to temporarily suspend the AstraZeneca COVID-19 vaccine

• MHRA response to the precautionary suspensions of COVID-19 Vaccine AstraZeneca

Related Articles:
Latest Articles: